Patent prosecution, opposition proceedings, nullity proceedings and litigation (patent infringement and compulsory licences) in the field of pharmaceutical and biotech intellectual property on ibandronate, neutrokine-alpha (BLys), HSA, BGH, insulin, interferons, interleukins, G-CSF, GM-CSF, EPO, tPA, genome project derived DNA inventions, BRCA1 and BRCA2, p10, recombinant viruses, vaccines (viral and bacterial), HPV diagnostics, gene therapy (e.g. of Duchenne muscular dystrophy), systems for the production of recombinant plants, transgenic animals, stem cells, bacterial, yeast and mammalian expression systems, humanized glycosylation in yeasts, methods for the purification of recombinantly produced proteins, antibody technology (monoclonals, single chain, single variable domain, humanized antibody design, anti-PD1-antibodies, anti-CD27-antibodies, trastuzumab, rituximab, golimumab, belimumab, brentuximab, ranibizumab, diabodies), PCR, Taq Man PCR, Taq polymerase and other thermostable enzymes, enzyme replacement therapies, NASBA, LCR, antisense technology, ribozymes, RNAi, CRISPR, patenting of research tools and functional genomics.
Member of the German Patent Attorney Bar Association, EPI, FICPI, AIPPI and GRUR.
PhD in molecular biology, 1984; German Patent Attorney, 1987; European Patent Attorney, 1988; European Trademark Attorney, 1995.
Numerous lectures and articles about patenting biotech inventions in the European Patent Office and the German Patent and Trademark Office and about enforcing such patents. Has published the book 'From Clones to Claims', Carl Heymanns Verlag, sixth edition, 2015, on biotech case law by the European Patent Office, co-authored by Jürgen Meier, Leslie McDonell and James F Haley Jr for the US jurisdiction and Yoshinori Hosoda for the Japanese jurisdiction.